We are aware that, based on the promising results of Checkmate 816 trial (Forde et al., 2022), neoadjuvant nivolumab plus chemotherapy has been approved by the FDA for treatment of EGFR/ALK-negative resectable NSCLC and also has been included in the 2022 NCCN V3 edition guideline recommendations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.